Arqule Inc (ARQL)

0.99
0.04 3.90
NASDAQ : Health Care
Prev Close 1.03
Open 1.04
Day Low/High 0.94 / 1.06
52 Wk Low/High 1.37 / 2.65
Volume 87.55K
Avg Volume 99.30K
Exchange NASDAQ
Shares Outstanding 71.17M
Market Cap 74.73M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ArQule Announces First Patient Dosed In Phase 1 Trial Of BTK Inhibitor, ARQ 531, For B-cell Malignancies

ArQule Announces First Patient Dosed In Phase 1 Trial Of BTK Inhibitor, ARQ 531, For B-cell Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies refractory to other approved therapies.

ArQule Presents Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of The European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid, Spain.

ArQule Announces First Patient Dosed In Company Sponsored Phase 1/2 Trial Of AKT Inhibitor, ARQ 092, For Rare Overgrowth Diseases

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with Overgrowth Diseases driven by genetic alterations of...

ArQule Presents Phase 1/2 Clinical Data With ARQ 087 In Intrahepatic Cholangiocarcinoma At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented at ASCO demonstrate a meaningful clinical benefit to intrahepatic...

ArQule To Present Preclinical Data For BTK Inhibitor, ARQ 531, At The 22nd Annual Congress Of The European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress in Madrid, Spain.

ArQule To Present Clinical Data At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that data from the phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, will be presented on June 3, 2017 at...

Arqule Reports First Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2017.

ArQule Announces Issuance Of U.S. Patent Covering Composition Of Matter Of Proprietary Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.

ArQule To Report First Quarter 2017 Financial Results On May 3, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter 2017 before the market opens on Wednesday, May 3, 2017.

ArQule Receives Clearance Of Investigational New Drug Application From The FDA For Proprietary Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq: ARQL) today announced that it has received clearance from the U.

ArQule To Present At The 16th Annual Needham Healthcare Conference On April 4, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule Announces Top-Line Results Of Phase 3 Clinical Study Of Tivantinib In Hepatocellular Carcinoma In Japan

ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of...

ArQule Reports Fourth Quarter And Full Year 2016 Financial Results

ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016.

ArQule To Report Fourth Quarter And Year End 2016 Financial Results On March 7, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year 2016 before the market opens on Tuesday, March 7, 2017.

Daiichi Sankyo And ArQule Announce The Completion Of The METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Treatment Of MET-Overexpressing Hepatocellular Carcinoma

ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival.

ArQule To Present At The Leerink Partners 6th Annual Global Healthcare Conference On February 15, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting

Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on Bruton's tyrosine kinase (BTK) inhibitor, ARQ 531, in a poster presentation by The Ohio State University at the American Society of...

Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting

Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University of Illinois College of Medicine at the American Society of...

ArQule Reports Third Quarter 2016 Financial Results

ArQule Reports Third Quarter 2016 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2016.

Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting

Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data will be presented on two molecules from its proprietary pipeline at the 2016 American Society of Hematology (ASH) Annual Meeting in San Diego,...

ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016

ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2016 before the market opens on Monday, November 7, 2016.

ArQule To Present At The Leerink Partners Rare Disease And Immuno-Oncology Roundtable On September 28, 2016

ArQule To Present At The Leerink Partners Rare Disease And Immuno-Oncology Roundtable On September 28, 2016

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule Announces Publication Of Manuscript Highlighting Preclinical Activity Of FGFR Inhibitor, ARQ 087, In Peer Reviewed Journal

ArQule Announces Publication Of Manuscript Highlighting Preclinical Activity Of FGFR Inhibitor, ARQ 087, In Peer Reviewed Journal

ArQule, Inc. (Nasdaq: ARQL) today announced the publication of a paper detailing the preclinical profile of ARQ 087, an orally available fibroblast growth factor receptor (FGFR) inhibitor.

ArQule Reports Second Quarter 2016 Financial Results

ArQule Reports Second Quarter 2016 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2016.